Presented by Dr Jon Tsai (Medical Head Oncology, Northern Europe Sanofi AB, Stockholm, Sweden)
In this video, Dr Jon Tsai, Medical Head for Oncology in Northern Europe at Sanofi, summarizes a study presented at the 2026 Annual Meeting of the International Myeloma Society (IMS) in Glasgow examining home treatment for patients with hematological malignancies in Sweden. The cross-sectional survey, conducted with Swedish academic partners, included 27 responses from nurses across all six healthcare regions.
Of the respondents, 24 (89%) reported to use home-based treatment, most commonly for acute myeloid leukemia, myelodysplastic syndromes, and multiple myeloma. Patient convenience was the primary reason for choosing home-based care. Subcutaneous injections were the most frequently administered treatments, although intravenous therapy was also provided in some cases. Self-administration by patients was relatively common, with medications typically collected from hospital pharmacies.
These findings suggest that home-based treatment is feasible and already widely implemented in Sweden. This approach may become increasingly relevant as the range of therapies suitable for administration outside the hospital setting is expected to expand substantially in the coming years.
Reference:
Tsai J, et al. IMS 2026; Abstract NSP-12.